138 related articles for article (PubMed ID: 2047690)
1. In vitro evaluation of antimicrobial compounds for cysticidal activity against Acanthamoeba.
Osato MS; Robinson NM; Wilhelmus KR; Jones DB
Rev Infect Dis; 1991; 13 Suppl 5():S431-5. PubMed ID: 2047690
[TBL] [Abstract][Full Text] [Related]
2. [In vitro study of propamidine isethionate: value in the follow-up of Acanthamoeba amebic keratitis].
Paniagua-Crespo E; Hasle DP; Aouizerate F; Volant A; Simitzis-Le Flohic AM
J Fr Ophtalmol; 1989; 12(6-7):489-91. PubMed ID: 2636245
[TBL] [Abstract][Full Text] [Related]
3. A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis.
Elder MJ; Kilvington S; Dart JK
Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):1059-64. PubMed ID: 8125716
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluations of topical agents to treat Acanthamoeba keratitis.
Sunada A; Kimura K; Nishi I; Toyokawa M; Ueda A; Sakata T; Suzuki T; Inoue Y; Ohashi Y; Asari S; Iwatani Y
Ophthalmology; 2014 Oct; 121(10):2059-65. PubMed ID: 24880905
[TBL] [Abstract][Full Text] [Related]
5. Synergy Testing of Antiamoebic Agents for Acanthamoeba: Antagonistic Effect of Voriconazole.
Talbott M; Cevallos V; Chen MC; Chin SA; Lalitha P; Seitzman GD; Lietman TM; Keenan JD
Cornea; 2019 Oct; 38(10):1309-1313. PubMed ID: 31306283
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of 19 Australian corneal isolates of Acanthamoeba.
Lim L; Coster DJ; Badenoch PR
Clin Exp Ophthalmol; 2000 Apr; 28(2):119-24. PubMed ID: 10933775
[TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of Acanthamoeba cysts in vitro using dimethylsulfoxide.
Saunders PP; Proctor EM; Rollins DF; Richards JS
Ophthalmology; 1992 Aug; 99(8):1197-200. PubMed ID: 1513571
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of effective treatment drugs against Acanthamoeba cyst].
Tahara K; Asari S; Shimomura Y; Endo T; Yanagihara T
Kansenshogaku Zasshi; 1997 Oct; 71(10):1025-30. PubMed ID: 9394554
[TBL] [Abstract][Full Text] [Related]
9. Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.
Kangussu-Marcolino MM; Ehrenkaufer GM; Chen E; Debnath A; Singh U
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():80-94. PubMed ID: 31707263
[TBL] [Abstract][Full Text] [Related]
10. In-vitro development of an effective treatment for Acanthamoeba keratitis.
Ortillés Á; Belloc J; Rubio E; Fernández MT; Benito M; Cristóbal JÁ; Calvo B; Goñi P
Int J Antimicrob Agents; 2017 Sep; 50(3):325-333. PubMed ID: 28709990
[TBL] [Abstract][Full Text] [Related]
11. Results of a trial of combined propamidine isethionate and neomycin therapy for Acanthamoeba keratitis. Brolene Study Group.
Hargrave SL; McCulley JP; Husseini Z
Ophthalmology; 1999 May; 106(5):952-7. PubMed ID: 10328395
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of In Vitro Antiamoebic Activity of Antimicrobial Agents Against Clinical Acanthamoeba Isolates.
Nakaminami H; Tanuma K; Enomoto K; Yoshimura Y; Onuki T; Nihonyanagi S; Hamada Y; Noguchi N
J Ocul Pharmacol Ther; 2017 Oct; 33(8):629-634. PubMed ID: 28704121
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance and Acanthamoeba keratitis: the quest for alternative antiprotozoal chemotherapy.
Hay J; Kirkness CM; Seal DV; Wright P
Eye (Lond); 1994; 8 ( Pt 5)():555-63. PubMed ID: 7835453
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of voriconazole anti-Acanthamoeba polyphaga in vitro activity, rat cornea penetration and efficacy against experimental rat Acanthamoeba keratitis.
Gueudry J; Le Goff L; Compagnon P; Lefevre S; Colasse E; Aknine C; Duval F; François A; Razakandrainibe R; Ballet JJ; Muraine M; Favennec L
J Antimicrob Chemother; 2018 Jul; 73(7):1895-1898. PubMed ID: 29596605
[TBL] [Abstract][Full Text] [Related]
15. Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine.
Seal D; Hay J; Kirkness C; Morrell A; Booth A; Tullo A; Ridgway A; Armstrong M
Eye (Lond); 1996; 10 ( Pt 4)():413-21. PubMed ID: 8944089
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Acanthamoeba keratitis: possibilities, problems, and new approaches].
Walochnik J; Duchêne M; Eibl H; Aspöck H
Wien Klin Wochenschr; 2003; 115 Suppl 3():10-7. PubMed ID: 15508774
[TBL] [Abstract][Full Text] [Related]
17. Cysticidal activity of antifungals against different genotypes of Acanthamoeba.
Iovieno A; Miller D; Ledee DR; Alfonso EC
Antimicrob Agents Chemother; 2014 Sep; 58(9):5626-8. PubMed ID: 25001304
[TBL] [Abstract][Full Text] [Related]
18. Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity.
Pérez-Santonja JJ; Kilvington S; Hughes R; Tufail A; Matheson M; Dart JK
Ophthalmology; 2003 Aug; 110(8):1593-600. PubMed ID: 12917179
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium.
Megha K; Sharma M; Sharma C; Gupta A; Sehgal R; Khurana S
Eye (Lond); 2022 Oct; 36(10):1911-1917. PubMed ID: 34548636
[TBL] [Abstract][Full Text] [Related]
20. The effects of freezing and antibiotics on the viability of Acanthamoeba cysts.
Matoba AY; Pare PD; Le TD; Osato MS
Arch Ophthalmol; 1989 Mar; 107(3):439-40. PubMed ID: 2923570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
